Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Ferrari, S; Bielack, SS; Smeland, S; Longhi, A; Egerer, G; Sundby Hall, K; Donati, D; Kevric, M; Brosjö, O; Comandone, A; Werner, M; Monge, O; Palmerini, E; Berdel, WE; Bjerkehagen, B; Paioli, A; Lorenzen, S; Eriksson, M; Gambarotti, M; Tunn, PU; Jebsen, NL; Cesari, M; von Kalle, T; Ferraresi, V; Schwarz, R; Bertulli, R; Kasparek, AK; Grignani, G; Krasniqi, F; Sorg, B; Hecker-Nolting, S; Picci, P; Reichardt, P.
EURO-B.O.S.S.: A European study on chemotherapy in bone-sarcoma patients aged over 40: Outcome in primary high-grade osteosarcoma.
Tumori. 2017; 104(1):30-36
Doi: 10.5301/tj.5000696
Web of Science
PubMed
FullText
FullText_MUG
- Co-Autor*innen der Med Uni Graz
- Kasparek Anne-Katrin
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- The EUROpean Bone Over 40 Sarcoma Study (EURO-B.O.S.S.) was the first prospective international study for patients 41-65 years old with high-grade bone sarcoma treated with an intensive chemotherapy regimen derived from protocols for younger patients with high-grade skeletal osteosarcoma. Chemotherapy based on doxorubicin, cisplatin, ifosfamide, and methotrexate was suggested, but patients treated with other regimens at the investigators' choice were also eligible for the study. The present report focuses on the subgroup of 218 patients with primary high-grade osteosarcoma. With a median follow-up of 47 months, the 5-year probability of overall survival (OS) was 66% in patients with localized disease and 22% in case of synchronous metastases. The 5-year OS in patients with localized disease was 29% in pelvic tumors, and 70% and 73% for extremity or craniofacial locations, respectively. In primary chemotherapy, tumor necrosis ≥90% was reported in 21% of the patients. There were no toxic deaths; however, hematological toxicity was considerable with 32% of patients experiencing 1 or more episodes of neutropenic fever. The incidence of nephrotoxicity and neurotoxicity (mainly peripheral) was 28% and 24%, respectively. After methotrexate, 23% of patients experienced delayed excretion, in 4 cases with nephrotoxicity. In patients over 40 years of age with primary high-grade osteosarcoma, an aggressive approach with chemotherapy and surgery can offer the probability of survival similar to that achieved in younger patients. Chemotherapy-related toxicity is significant and generally higher than that reported in younger cohorts of osteosarcoma patients treated with more intensive regimens.
- Find related publications in this database (using NLM MeSH Indexing)
- Adult -
- Aged -
- Antineoplastic Combined Chemotherapy Protocols - adverse effects
- Antineoplastic Combined Chemotherapy Protocols - therapeutic use
- Bone Neoplasms - drug therapy
- Bone Neoplasms - pathology
- Cisplatin - administration & dosage
- Cisplatin - adverse effects
- Doxorubicin - administration & dosage
- Doxorubicin - adverse effects
- Europe -
- Febrile Neutropenia - chemically induced
- Female -
- Humans -
- Ifosfamide - administration & dosage
- Ifosfamide - adverse effects
- International Cooperation -
- Male -
- Methotrexate - administration & dosage
- Methotrexate - adverse effects
- Middle Aged -
- Osteosarcoma - drug therapy
- Osteosarcoma - pathology
- Prospective Studies -
- Survival Analysis -
- Treatment Outcome -
- Find related publications in this database (Keywords)
- Adult osteosarcoma
- Chemotherapy
- Chemotherapy-related toxicity
- Osteosarcoma